Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes

Abstract

Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.

1 . Use of an Interleukin 1 receptor antagonist (IL-1Ra) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal. 
     
     
         2 . The use according to  claim 1 , wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant protein (rIL-1Ra). 
     
     
         3 . The use according to  claim 1 , wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra). 
     
     
         4 . The use according to  claim 1 , wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC). 
     
     
         5 . The use according to  claim 1 , wherein the medicament is adapted for parenteral administration. 
     
     
         6 . Use of pyrrolidinedithiocarbamate (PDTC) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal. 
     
     
         7 . The use according to  claim 6 , wherein the medicament is adapted for parenteral administration. 
     
     
         8 . A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of an Interleukin 1 receptor antagonist (11-IRa). 
     
     
         9 . The method according to  claim 8 , wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant protein (rIL-1Ra). 
     
     
         10 . The method according to  9 , wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra). 
     
     
         11 . The method according to  claim 8 , wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC). 
     
     
         12 . The method according to  claim 8 , wherein the medicament is adapted for parenteral administration. 
     
     
         13 . A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of pyrrolidinedithiocarbamate (PDTC). 
     
     
         14 . The method according to  claim 13 , wherein the medicament is adapted for parenteral administration.